Trend
DailyUptrend (confirmed)
4 hourSymmetric Triangle
1 hourSymmetric Triangle
15 minExpanding
5 minConsolidating
Daily trend turns down below $3.76
Key levels
Resistance$7.11
Resistance$5.99
Support$5.43
Support$4.68
Latest news & SEC filings
No headlines in the last 90 days.
Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing cancer therapies that activate the body's immune system. Its lead candidate, BDC-4182, is an immune-stimulating antibody conjugate directed at the claudin 18.2 protein and is being tested in patients with gastric and gastroesophageal junction tumors. The company also has earlier-stage programs against other cancer targets and research partnerships with Genmab and Toray. Bolt uses contract manufacturers and has no approved products.
Based on the company's 10-K filed Mar 12, 2026.
Nasdaq · Healthcare
SEPT Low Target
$7.00
SEPT Mid Target
$14.50
SEPT High Target
$22.00
Analyst Consensus
$14.50
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for BOLT.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$15.70
14
Moat Score
NONE
4/9
Piotroski Score
-12.6
Altman Z-Score
Insider Signal
NEUTRAL
5 buys / 9 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Coastlands Capital LP | 10% owner | Buy | 50,000 | $319K | Nov 9, 2026 |
| GUJRATHI SHEILA | director officer | Buy | 72,766 | - | Oct 23, 2026 |
| GUJRATHI SHEILA | director officer | Buy | 13,055 | - | Oct 23, 2026 |
| Yonehiro Grant | officer | Sale | 6,850 | $22K | Sep 18, 2026 |
| Nemec Sarah | officer | Sale | 4,077 | $13K | Sep 18, 2026 |
| Quinn William P. | director officer | Sale | 9,132 | $30K | Sep 18, 2026 |
| Yonehiro Grant | officer | Sale | 4,909 | $16K | Sep 17, 2026 |
| Nemec Sarah | officer | Sale | 2,922 | $10K | Sep 17, 2026 |
| Quinn William P. | director officer | Sale | 6,545 | $22K | Sep 17, 2026 |
| Yonehiro Grant | officer | Sale | 1,417 | $5K | Sep 16, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
0.1%
3yr Revenue CAGR
10.3%
EPS Growth YoY
46.01%
FCF Growth YoY
34.9%
Revenue Trend
STABLE
SEPT Investing tracks real-time dark pool institutional trades for BOLT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:57:02 | $5.98 | 1,196 | $$7K | BUY |
| 17:05:08 | $6.08 | 2,200 | $$13K | BUY |
| 20:59:27 | $6.33 | 6,000 | $$38K | BUY |
| 20:12:06 | $6.34 | 1,400 | $$9K | BUY |
| 20:01:47 | $6.32 | 1,700 | $$11K | MIDPOINT |
5 dark pool trades shown · $$78K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Bolt Biotherapeutics, Inc. (BOLT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Bolt Biotherapeutics, Inc. (BOLT) is at $5.91, down 5.59% (-$0.35) at the Nov 12, 2026 close.
The average analyst price target for BOLT is $14.50, ranging from $7 to $22, based on 2 analysts. Latest: Rodman & Renshaw initiates on May 29, 2026.
Analyst ratings for BOLT: 0 Buy, 2 Hold, 0 Sell — consensus Hold.
BOLT last reported on Aug 11, 2026: EPS -$4.57 vs -$3.39 expected — a miss of 34.8%.
BOLT does not currently pay a dividend.
Support: $5.43, $4.68, $3.76. Resistance: $5.99, $7.11, $7.78.
Insider activity: NEUTRAL, 5 buys and 9 sells in the last 90 days.